Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Sarcoma, Kaposi 3Epstein-Barr Virus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Pyloric Stenosis, Hypertrophic 1Nasopharyngeal Carcinoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Immune Reconstitution Inflammatory Syndrome 1Cytomegalovirus Infections 1Castleman Disease 1

Interventions

Rituximab 5Valganciclovir 2Methotrexate 2Leucovorin 2Doxorubicin 2valomaciclovir 1threonic acid 1pembrolizumab 1otelixizumab 1merphos 1cc-486 1avelumab 1Zidovudine 1Vincristine 1Valacyclovir 1Tomography, X-Ray Computed 1Prednisone 1Magnesium Sulfate 1Interferons 1Hydroxyurea 1Etoposide 1Echocardiography 1EPOCH protocol 1Cyclophosphamide 1Caves 1Carboplatin 1Brentuximab Vedotin 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Epstein-Barr Virus Infections × Valganciclovir × Clear all
NCT05011058 2025-07-28

NAVAL-1

Viracta Therapeutics, Inc.

Phase 2 Terminated
102 enrolled 28 charts

Epstein-Barr Virus Infections, Pyloric Stenosis, Hypertrophic

NCT01972035 2022-04-12

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

University of Minnesota

Phase 2 Completed
137 enrolled 8 charts

Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡